title: Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.
abstract: Body composition was determined using dual-energy X-ray absorptiometry (DXA) in a subset of patients without (BLOSSOM) and with (BLOOM-DM) type 2 diabetes who received diet and exercise counselling along with either lorcaserin 10 mg twice daily or placebo. DXA scans were performed on study day 1 (baseline), week 24 and week 52. Baseline demographics of the subpopulations (without diabetes, n = 189; with diabetes, n = 63) were similar between studies and representative of their study populations. At week 52, patients without diabetes on lorcaserin lost significantly more fat mass relative to those on placebo (-12.06% vs -5.93%; p = 0.008). In patients with diabetes, fat mass was also decreased with lorcaserin relative to placebo (-9.87% vs -1.65%; p < 0.05). More fat mass was lost in the trunk region with lorcaserin compared with placebo (without diabetes: -3.31% vs -2.05%; with diabetes: -3.65% vs -0.36%). Weight loss with lorcaserin was associated with a greater degree of fat mass loss than lean mass loss, and most of the fat mass lost for patients without and with diabetes was from the central region of the body.
authors.affiliation: Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
authors.forename: C
authors.identifier: 0000-0002-8029-1922
authors.initials: C
authors.lastname: Apovian
authors.affiliation: Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Palmer
authors.affiliation: Formerly of Eisai Inc., Woodcliff Lake, NJ, USA.
authors.forename: R
authors.initials: R
authors.lastname: Fain
authors.affiliation: Eisai Inc., Woodcliff Lake, NJ, USA.
authors.forename: C
authors.initials: C
authors.lastname: Perdomo
authors.affiliation: Washington Center for Weight Management and Research, Arlington, VA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Rubino
mesh_terms: D015502:Absorptiometry, Photon; D000273:Adipose Tissue / Q000000981:diagnostic imaging*; D000328:Adult; D001552:Benzazepines / Q000627:therapeutic use*; D001823:Body Composition; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism*; D004035:Diet Therapy; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D050177:Overweight / Q000150:complications / Q000378:metabolism / Q000628:therapy; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists / Q000627:therapeutic use*
chemical_list: D001552:Benzazepines; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; C506658:lorcaserin
keywords: antiobesity drug; appetite control; body composition; clinical trial; obesity therapy